Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Incidence and Severity of Adverse Drug Reactions in Medical Intensive Care Unit

Author(s): Sana Shaikh, Asawari Raut*, Prajkta Jambhale, Shivkumar Iyer and Jignesh Shah

Volume 19, Issue 3, 2024

Published on: 06 September, 2023

Page: [332 - 341] Pages: 10

DOI: 10.2174/1574886318666230816090606

Price: $65

Abstract

Background: Adverse drug reactions (ADRs) curtail patients’ quality of life by virtue of increasing therapeutic complexity and rising multimorbidity. In India, the frequency of ADRs for individual drugs and their economic burdens are rarely evaluated. This study aimed at identifying the incidence and severity of ADRs leading to hospitalization (ADRA) and occurring during a hospital stay (ADRH).

Objective: The objective of this study is to evaluate the incidence the incidence and severity of ADRs in the ICU and their impact on the duration of hospitalization, along with the cost incurred to treat ADRs in the ICU.

Methods: Demographic, clinical, and pharmacological data on patients admitted to the ICU were collected, analyzed and evaluated for ADRs. According to the setting analyzed, a descriptive analysis of the reactions, suspected medicines, and associated factors was undertaken.

Results: A total of 208 patients were admitted to the ICU during the study period, of which ADRA contributed 9.1% of the incidence rate and 8.1% of ADRH in 36 patients. Males had a higher incidence of ADRs than females. Patients who had ADRs had a substantially longer length of stay than those who did not. Electrolyte disturbance was the most commonly found ADR. According to the Hartwig scale and WHO-causality scale, 88.9% were moderate, and 97.2% were possible ADRs, respectively.

Conclusion: In this study, a similar incidence rate of ADRA and ADRH was observed. The average cost for treating ADRA was higher than that for treating ADRH. As a result, identifying and preventing these reactions is critical, as they cause the patient greater suffering.

« Previous Next »
Graphical Abstract

[1]
Edwards IR, Aronson JK. Adverse drug reactions: Definitions, diagnosis, and management. Lancet 2000; 356(9237): 1255-9.
[http://dx.doi.org/10.1016/S0140-6736(00)02799-9] [PMID: 11072960]
[2]
Stingeni L, Bianchi L, Tramontana M, et al. Skin tests in the diagnosis of adverse drug reactions. G Ital Dermatol Venereol 2020; 155(5): 602-21.
[http://dx.doi.org/10.23736/S0392-0488.20.06698-5] [PMID: 32938165]
[3]
Alomar MJ. Factors affecting the development of adverse drug reactions. Saudi Pharm J 2014; 22(2): 83-94.
[http://dx.doi.org/10.1016/j.jsps.2013.02.003] [PMID: 24648818]
[4]
Kalaiselvan V, Thota P, Singh G. Pharmacovigilance Programme of India: Recent developments and future perspectives. Indian J Pharmacol 2016; 48(6): 624-8.
[http://dx.doi.org/10.4103/0253-7613.194855] [PMID: 28066097]
[5]
Baker GS, Norton PG, Flintoft V. The Canadian Adverse Events Study: The incidence of adverse events among hospital patients in Canada. CMAJ 2004 May 25; 170(11): 1678-86.
[6]
Kongkaew C, Noyce PR, Ashcroft DM. Hospital admissions associated with adverse drug reactions: A systematic review of prospective observational studies. Ann Pharmacother 2008; 42(7-8): 1017-25.
[http://dx.doi.org/10.1345/aph.1L037] [PMID: 18594048]
[7]
Davies E, Green C, Mottram D, Pirmohamed M. Adverse drug reactions in hospitals: A narrative review. Curr Drug Saf 2007; 2(1): 79-87.
[http://dx.doi.org/10.2174/157488607779315507] [PMID: 18690953]
[8]
Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Determinants of under-reporting of adverse drug reactions: A systematic review. Drug Saf 2009; 32(1): 19-31.
[http://dx.doi.org/10.2165/00002018-200932010-00002] [PMID: 19132802]
[9]
Güzey C, Spigset O. Genotyping as a tool to predict adverse drug reactions. Curr Top Med Chem 2004; 4(13): 1409-19.
[http://dx.doi.org/10.2174/1568026043387791] [PMID: 15379654]
[10]
Wagner DP, Draper EA. Acute physiology and chronic health evaluation (APACHE II) and Medicare reimbursement. Health Care Financ Rev 1984; 1984(Suppl): 91-105.
[PMID: 10311080]
[11]
Petrova G, Stoimenova A, Dimitrova M, Kamusheva M, Petrova D, Georgiev O. Assessment of the expectancy, seriousness and severity of adverse drug reactions reported for chronic obstructive pulmonary disease therapy. SAGE Open Med 2017; 5: 2050312117690404.
[http://dx.doi.org/10.1177/2050312117690404] [PMID: 28228952]
[12]
The use of the WHO-UMC system for standardised case causality assessment. 2013. Available From: https://www.who.int/publications/m/item/WHO-causality-assessment
[13]
Arnaiz JA, Carné X, Riba N, Codina C, Ribas J, Trilla A. The use of evidence in pharmacovigilance. Eur J Clin Pharmacol 2001; 57(1): 89-91.
[http://dx.doi.org/10.1007/s002280100265] [PMID: 11372600]
[14]
Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf 1999; 20(2): 109-17.
[http://dx.doi.org/10.2165/00002018-199920020-00002] [PMID: 10082069]
[15]
Humphrey GF. Scientific fraud: The McBride case. Med Sci Law 1992; 32(3): 199-203.
[http://dx.doi.org/10.1177/002580249203200303] [PMID: 1513217]
[16]
Ramesh M, Pandit J, Parthasarathi G. Adverse drug reactions in a South Indian hospital? their severity and cost involved. Pharmacoepidemiol Drug Saf 2003; 12(8): 687-92.
[http://dx.doi.org/10.1002/pds.871] [PMID: 14762985]
[17]
Chan SL, Ang X, Sani LL, et al. Prevalence and characteristics of adverse drug reactions at admission to hospital: A prospective observational study. Br J Clin Pharmacol 2016; 82(6): 1636-46.
[http://dx.doi.org/10.1111/bcp.13081] [PMID: 27640819]
[18]
Gandhi TK, Weingart SN, Borus J, et al. Adverse drug events in ambulatory care. N Engl J Med 2003; 348(16): 1556-64.
[http://dx.doi.org/10.1056/NEJMsa020703] [PMID: 12700376]
[19]
Jha N, Bajracharya O, Namgyal T. Prevalence of adverse drug reactions with commonly prescribed drugs in different hospitals of Kathmandu valley. Kathmandu Univ Med J 2007; 5(4): 504-10.
[PMID: 18604084]
[20]
Jose J, Rao PGM, Archana B. Implementation and results of an adverse drug reaction reporting programme at an Indian teaching hospital. Indian J Pharmacol 2006; 38(4): 293.
[http://dx.doi.org/10.4103/0253-7613.27032]
[21]
Akhideno PE, Fasipe OJ, Isah AO. The incidence and prevalence of adverse drug reactions among medical inpatients in a Nigerian University Teaching Hospital. J Curr Res Sci Med 2018; 4(2): 86-93.
[22]
Lagnaoui R, Moore N, Fach J, Longy-Boursier M, Bégaud B. Adverse drug reactions in a department of systemic diseases-oriented internal medicine: Prevalence, incidence, direct costs and avoidability. Eur J Clin Pharmacol 2000; 56(2): 181-6.
[http://dx.doi.org/10.1007/s002280050738] [PMID: 10877014]
[23]
Ruiter R, Visser LE, Rodenburg EM, Trifirò G, Ziere G, Stricker BH. Adverse drug reaction-related hospitalizations in persons aged 55 years and over: A population-based study in the Netherlands. Drugs Aging 2012; 29(3): 225-32.
[http://dx.doi.org/10.2165/11599430-000000000-00000] [PMID: 22372725]
[24]
Zazzara MB, Palmer K, Vetrano DL, Carfì A, Onder G. Adverse drug reactions in older adults: A narrative review of the literature. Eur Geriatr Med 2021; 12(3): 463-73.
[http://dx.doi.org/10.1007/s41999-021-00481-9] [PMID: 33738772]
[25]
Koh Y, Kutty FBM, Li SC. Drug-related problems in hospitalized patients on polypharmacy: The influence of age and gender. Ther Clin Risk Manag 2005; 1(1): 39-48.
[http://dx.doi.org/10.2147/tcrm.1.1.39.53597] [PMID: 18360542]
[26]
Hurwitz N, Wade OL. Intensive hospital monitoring of adverse reactions to drugs. BMJ 1969; 1(5643): 531-6.
[http://dx.doi.org/10.1136/bmj.1.5643.531] [PMID: 5764699]
[27]
Calderón-Larrañaga A, Poblador-Plou B, González-Rubio F, Gimeno-Feliu LA, Abad-Díez JM, Prados-Torres A. Multimorbidity, polypharmacy, referrals, and adverse drug events: Are we doing things well? Br J Gen Pract 2012; 62(605): e821-6.
[http://dx.doi.org/10.3399/bjgp12X659295] [PMID: 23211262]
[28]
Bassi PU, Osakwe AI, Ogar CK, et al. Impact of comorbidity on adverse drug reaction profile in a cohort of patients treated with Artemisinin combination therapies for uncomplicated malaria in Nigeria. Pharmacol Res Perspect 2017; 5(2): e00302.
[http://dx.doi.org/10.1002/prp2.302] [PMID: 28357128]
[29]
Singh A, Dwivedi S. Study of adverse drug reactions in patients with diabetes attending a tertiary care hospital in New Delhi, India. Indian J Med Res 2017; 145(2): 247-9.
[PMID: 28639602]
[30]
Lavan AH, Gallagher P. Predicting risk of adverse drug reactions in older adults. Ther Adv Drug Saf 2016; 7(1): 11-22.
[http://dx.doi.org/10.1177/2042098615615472] [PMID: 26834959]
[31]
Markgraf R, Deutschinoff G, Pientka L, Scholten T. Comparison of Acute Physiology and Chronic Health Evaluations II and III and Simplified Acute Physiology Score II: A prospective cohort study evaluating these methods to predict outcome in a German interdisciplinary intensive care unit. Crit Care Med 2000; 28(1): 26-33.
[http://dx.doi.org/10.1097/00003246-200001000-00005] [PMID: 10667495]
[32]
Knaus WA, Draper EA, Wagner DP, Zimmerman JE. An evaluation of outcome from intensive care in major medical centers. Ann Intern Med 1986; 104(3): 410-8.
[http://dx.doi.org/10.7326/0003-4819-104-3-410] [PMID: 3946981]
[33]
Joseph SG, Badyal DK. Spontaneous Adverse Drug Reaction Monitoring in A Tertiary Care Hospital in Northern India. Curr Drug Saf 2020; 15(3): 215-21.
[34]
Ganesan S, Sandhiya S, Subrahmanyam DK. Frequency of ADRs and their Economic Impact in a Tertiary Care Public Sector Hospital in South India. J Basic. Clin Appl Health Sci 2020; 3(1): 23-31.
[http://dx.doi.org/10.5005/jp-journals-10082-02235]
[35]
Bordet R, Gautier S, Le Louet H, Dupuis B, Caron J. Analysis of the direct cost of adverse drug reactions in hospitalised patients. Eur J Clin Pharmacol 2001; 56(12): 935-41.
[http://dx.doi.org/10.1007/s002280000260] [PMID: 11317484]
[36]
Lisha J, Annalakshmi V, Maria J, Padmini D. Adverse drug reactions in critical care settings: A systematic review. Curr Drug Saf 2017; 12(3): 147-61.
[PMID: 28699492]
[37]
Suh DC, Woodall BS, Shin SK, Santis ERH-D. Clinical and economic impact of adverse drug reactions in hospitalized patients. Ann Pharmacother 2000; 34(12): 1373-9.
[http://dx.doi.org/10.1345/aph.10094] [PMID: 11144691]
[38]
Cooper JW. Adverse drug reaction-related hospitalizations of nursing facility patients: A 4-year study. South Med J 1999; 92(5): 485-90.
[http://dx.doi.org/10.1097/00007611-199905000-00007] [PMID: 10342894]
[39]
Panthakalam S, Bhatnagar D, Klimiuk P. The prevalence and management of hyperglycaemia in patients with rheumatoid arthritis on corticosteroid therapy. Scott Med J 2004; 49(4): 139-41.
[http://dx.doi.org/10.1177/003693300404900407] [PMID: 15648707]
[40]
Blackburn D, Hux J, Mamdani M. Quantification of the risk of corticosteroid-induced diabetes mellitus among the elderly. J Gen Intern Med 2002; 17(9): 717-20.
[http://dx.doi.org/10.1046/j.1525-1497.2002.10649.x] [PMID: 12220369]
[41]
Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, Pirmohamed M. Adverse drug reactions in hospital in-patients: A prospective analysis of 3695 patient-episodes. PLoS One 2009; 4(2): e4439.
[http://dx.doi.org/10.1371/journal.pone.0004439] [PMID: 19209224]
[42]
Riedl MA, Casillas AM. Adverse drug reactions: Types and treatment options. Am Fam Physician 2003; 68(9): 1781-90.
[PMID: 14620598]
[43]
Wu L, Ingle T, Liu Z, et al. Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA. BMC Bioinformatics 2019; 20(S2) (Suppl. 2): 97.
[http://dx.doi.org/10.1186/s12859-019-2628-5] [PMID: 30871458]
[44]
Miltiadous G, Mikhailidis DP, Elisaf M. Acid-base and electrolyte abnormalities observed in patients receiving cardiovascular drugs. J Cardiovasc Pharmacol Ther 2003; 8(4): 267-76.
[http://dx.doi.org/10.1177/107424840300800404] [PMID: 14740076]
[45]
Shamna M, Dilip C, Ajmal M, et al. A prospective study on Adverse Drug Reactions of antibiotics in a tertiary care hospital. Saudi Pharm J 2014; 22(4): 303-8.
[http://dx.doi.org/10.1016/j.jsps.2013.06.004] [PMID: 25161373]
[46]
Chawla S, Kalra BS, Dharmshaktu P, Sahni P. Adverse drug reaction monitoring in a tertiary care teaching hospital. J Pharmacol Pharmacother 2011; 2(3): 196-8.
[http://dx.doi.org/10.4103/0976-500X.83291] [PMID: 21897720]
[47]
Shukla AK, Jhaj R, Misra S, Ahmed SN. Agreement between WHO-UMC causality scale and the Naranjo algorithm for causality assessment of adverse drug reactions. J Family Med Prim Care 2021; 10(9): 3303-8.
[48]
Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. JAMA 1998; 279(15): 1200-5.
[http://dx.doi.org/10.1001/jama.279.15.1200] [PMID: 9555760]
[49]
Lihite RJ, Lahkar M, Das S, et al. A study on adverse drug reactions in a tertiary care hospital of Northeast India. Alex J Med 2017; 53(2): 151-6.
[http://dx.doi.org/10.1016/j.ajme.2016.05.007]
[50]
Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Health Syst Pharm 1992; 49(9): 2229-32.
[http://dx.doi.org/10.1093/ajhp/49.9.2229] [PMID: 1524068]
[51]
Fasipe OJ, Akhideno PE, Isah AO, Owhin OS. A prospective study on causality assessment rating, mortality rate, and case fatality rate for adverse drug reactions among medical inpatients at the University of Benin Teaching Hospital, Nigeria. Med J Dr Patil Vidyapeeth 2019; 12(5): 398.
[http://dx.doi.org/10.4103/mjdrdypu.mjdrdypu_224_18]
[52]
Joseph SG, Badyal D. Spontaneous adverse drug reaction monitoring in a tertiary care hospital in Northern India. JK Sci 2016; 18: 103-6.
[53]
Venkatasubbaiah M, Dwarakanadha Reddy P, Satyanarayana SV. Analysis and reporting of adverse drug reactions at a tertiary care teaching hospital. Alex J Med 2018; 54(4): 597-603.
[http://dx.doi.org/10.1016/j.ajme.2018.10.005]
[54]
Chan ALF, Lee HY, Ho CH, Cham TM, Lin SJ. Cost evaluation of adverse drug reactions in hospitalized patients in Taiwan: A prospective, descriptive, observational study. Curr Ther Res Clin Exp 2008; 69(2): 118-29.
[http://dx.doi.org/10.1016/j.curtheres.2008.04.005] [PMID: 24692791]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy